DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13346
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMurugesan, Sankaranarayanan-
dc.date.accessioned2023-12-11T10:48:29Z-
dc.date.available2023-12-11T10:48:29Z-
dc.date.issued2021-01-
dc.identifier.urihttps://www.future-science.com/doi/10.4155/fmc-2020-0257-
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13346-
dc.description.abstractReverse transcriptase and integrase are key enzymes that play a pivotal role in HIV-1 viral maturation and replication. Reverse transcriptase consists of two active sites: RNA-dependent DNA polymerase and RNase H. The catalytic domains of integrase and RNase H share striking similarity, comprising two aspartates and one glutamate residue, also known as the catalytic DDE triad, and a Mg2+ pair. The simultaneous inhibition of reverse transcriptase and integrase can be a rational drug discovery approach for combating the emerging drug resistance problem. In the present review, the dual inhibition of RNase H and integrase is systematically discussed, including rationality of design, journey of development, advancement and future perspectiveen_US
dc.language.isoenen_US
dc.publisherFuture Science Groupen_US
dc.subjectPharmacyen_US
dc.subjectDual inhibitionen_US
dc.subjectReverse transcriptase (RT)en_US
dc.subjectIntegraseen_US
dc.subjectMolecular hybridizationen_US
dc.subjectResistancereverse transcriptaseen_US
dc.titleSearch for new therapeutics against HIV-1 via dual inhibition of RNase H and integrase: current status and future challengesen_US
dc.typeArticleen_US
Appears in Collections:Department of Pharmacy

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.